C4.4A is associated with tumor budding and epithelial-mesenchymal transition of colorectal cancer

Cancer Science

Volumn 103, Issue 6, 2012, Pages 1155-1164

  Oshiro, Ryota ^a   Yamamoto, Hirofumi ^a   Takahashi, Hidekazu ^a   Ohtsuka, Masahisa ^a   Wu, Xin ^a   Nishimura, Junichi ^a   Takemasa, Ichiro ^a   Mizushima, Tsunekazu ^a   Ikeda, Masataka ^a   Sekimoto, Mitsugu ^a   Matsuura, Nariaki ^a   Doki, Yuichiro ^a   Mori, Masaki ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; C4.4AA PROTEIN; KI 67 ANTIGEN; MEMBRANE PROTEIN; NERVE CELL ADHESION MOLECULE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ADVANCED CANCER; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CELL BUDDING; CELL PROLIFERATION; CELL STRUCTURE; COLORECTAL CANCER; CONTROLLED STUDY; DISTANT METASTASIS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; TUMOR VOLUME;

BETA CATENIN; CADHERINS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLORECTAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; GPI-LINKED PROTEINS; HUMANS; KI-67 ANTIGEN; MEMBRANE PROTEINS; NEOPLASM INVASIVENESS; PROGNOSIS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL; VIMENTIN;

EID: 84861678334     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02263.x     Document Type: Article

References (39)

1. Matzku S, Wenzel A, Liu S, Zller M. Antigenic differences between metastatic and nonmetastatic BSp73 rat tumor variants characterized by monoclonal antibodies. Cancer Res 1989; 49: 1294.
2. Claas C, Herrmann K, Matzku S, Mller P, Zller M. Developmentally regulated expression of metastasis-associated antigens in the rat. Cell Growth Differ 1996; 7: 663.
3. Roesel M, Claas C, Seiter S, Herlevsen M, Zoeller M. Cloning and functional characterization of a new phosphatidyl-inositol anchored molecule of a metastasizing rat pancreatic tumor. Oncogene 1998; 17: 1989-2002.
4. Wurfel J, Seiter S, Stassar M et al. Cloning of the human homologue of the metastasis-associated rat C4. 4A. Gene 2001; 262: 35-41.
5. Smith BA, Kennedy WJ, Harnden P, Selby PJ, Trejdosiewicz LK, Southgate J. Identification of genes involved in human urothelial cell-matrix interactions: implications for the progression pathways of malignant urothelium. Cancer Res 2001; 61: 1678.
6. Hansen LV, Grdsvoll H, Nielsen BS et al. Structural analysis and tissue localization of human C4. 4A: a protein homologue of the urokinase receptor. Biochem J 2004; 380: 845.
7. Seiter S, Stassar M, Rappl G, Reinhold U, Tilgen W, Zller M. Upregulation of C4. 4 A expression during progression of melanoma. J Investig Dermatol 2001; 116: 344-7.
8. Fletcher G, Patel S, Tyson K et al. hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4. 4a and dystroglycan. Br J Cancer 2003; 88: 579-85.
9. Hansen LV, Skov BG, Ploug M, Pappot H. Tumour cell expression of C4. 4A, a structural homologue of the urokinase receptor, correlates with poor prognosis in non-small cell lung cancer. Lung Cancers 2007; 58: 260-6.
10. Paret C, Hildebrand D, Weitz J et al. C4. 4A as a candidate marker in the diagnosis of colorectal cancer. Br J Cancer 2007; 97: 1146-56.
11. Ueno H, Murphy J, Jass J, Mochizuki H, Talbot I. Tumourbudding'as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 2002; 40: 127-32.
12. Hase K, Shatney C, Johnson D, Trollope M, Vierra M. Prognostic value of tumor "budding" in patients with colorectal cancer. Dis Colon Rectum 1993; 36: 627-35.
13. Nakanishi Y, Ohara M, Doumen H, Kimura N, Ishidate T, Kondo S. Correlation between tumor budding and post-resection prognosis in patients with invasive squamous cell carcinoma of the thoracic esophagus. World J Surg 2010; 35: 1-8.
14. Tanaka M. Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for stage II, T3 colon cancer. Dis Colon Rectum 2003; 46: 1054-9.
15. Ueno H, Mochizuki H, Hashiguchi Y, Hatsuse K, Fujimoto H, Hase K. Predictors of extrahepatic recurrence after resection of colorectal liver metastases. Br J Surg 2004; 91: 327-33.
16. Ueno H, Mochizuki H, Hashiguchi Y et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 2004; 127: 385-94.
17. Shinto E, Jass JR, Tsuda H et al. Differential prognostic significance of morphologic invasive markers in colorectal cancer: tumor budding and cytoplasmic podia. Dis Colon Rectum 2006; 49: 1422-30.
18. Tateishi Y, Nakanishi Y, Taniguchi H, Shimoda T, Umemura S. Pathological prognostic factors predicting lymph node metastasis in submucosal invasive (T1) colorectal carcinoma. Mod Pathol 2010; 23: 1068-72.
19. Gospodarowicz MK, O'Sullivan B, Sobin LH. Cancer IUa. Prognostic Factors in Cancer. Hoboken, NJ: Wiley-Liss, 2006.
20. Konishi K, Yamamoto H, Mimori K et al. Expression of C4. 4A at the invasive front is a novel prognostic marker for disease recurrence of colorectal cancer. Cancer Sci 2010; 101: 2269-77.
21. Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget 2010; 1: 651-61.
22. Wang C, Huang H, Huang Z et al. Tumor budding correlates with poor prognosis and epithelial-mesenchymal transition in tongue squamous cell carcinoma. J Oral Pathol Med 2011; 40: 545-51.
23. Jang TJ. Expression of E-cadherin and β-catenin is altered at tumor budding sites, whose number is associated with the progression of colorectal carcinoma. Korean J Pathol 2009; 43: 523.
24. Hayashi N, Yamamoto H, Hiraoka N et al. Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm. Hepatology 2001; 34: 638-50.
25. Noura S, Yamamoto H, Ohnishi T et al. Comparative detection of lymph node micrometastases of stage II colorectal cancer by reverse transcriptase polymerase chain reaction and immunohistochemistry. J Clin Oncol 2002; 20: 4232.
26. Hoshino H, Miyoshi N, Nagai K et al. Epithelial-mesenchymal transition with expression of SNAI1-induced chemoresistance in colorectal cancer. Biochem Biophys Res Commun 2009; 390: 1061-5.
27. Yamamoto H, Kondo M, Nakamori S, Nagano H. JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis1, * 1. Gastroenterology 2003; 125: 556-71.
28. Makino T, Yamasaki M, Takeno A et al. Cytokeratins 18 and 8 are poor prognostic markers in patients with squamous cell carcinoma of the oesophagus. Br J Cancer 2009; 101: 1298-306.
29. Wang LM, Kevans D, Mulcahy H et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg pathol 2009; 33: 134.
30. Nakamura T, Mitomi H, Kanazawa H, Ohkura Y, Watanabe M. Tumor budding as an index to identify high-risk patients with stage II colon cancer. Dis Colon Rectum 2008; 51: 568-72.
31. Kanazawa H, Mitomi H, Nishiyama Y et al. Tumour budding at invasive margins and outcome in colorectal cancer. Colorectal Dis 2008; 10: 41-7.
32. Märkl B, Renk PI, Oruzio DV et al. Tumour budding, uPA and PAI-1 are associated with aggressive behaviour in colon cancer. J Surg Oncol 2010; 102: 235-41.
33. Ogawa T, Yoshida T, Tsuruta T et al. Tumor budding is predictive of lymphatic involvement and lymph node metastases in submucosal invasive colorectal adenocarcinomas and in non-polypoid compared with polypoid growths. Scand J Gastroenterol 2009; 44: 605-14.
34. Okuyama T, Oya M, Ishikawa H. Budding as a risk factor for lymph node metastasis in pT1 or pT2 well-differentiated colorectal adenocarcinoma. Dis Colon Rectum 2002; 45: 628-34.
35. Koike M, Kodera Y, Itoh Y et al. Multivariate analysis of the pathologic features of esophageal squamous cell cancer: tumor budding is a significant independent prognostic factor. Ann Surg Oncol 2008; 15: 1977-82.
36. Masaki T, Matsuoka H, Sugiyama M et al. Laminin-5 f{hook}Á2 chain expression as a possible determinant of tumor aggressiveness in T1 colorectal carcinomas. Dig Dis Sci 2003; 48: 272-8.
37. Pyke C, Rmer J, Kallunki P et al. The gamma 2 chain of kalinin/laminin 5 is preferentially expressed in invading malignant cells in human cancers. Am J Pathol 1994; 145: 782.
38. Nilsson PJ. Tumour budding detected by laminin-5 2-chain immunohistochemistry is of prognostic value in epidermoid anal cancer. Ann Oncol 2005; 16: 893-8.
39. Ngan C, Yamamoto H, Seshimo I et al. Quantitative evaluation of vimentin expression in tumour stroma of colorectal cancer. Br J Cancer 2007; 96: 986-92.